Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action
Open accessAbstract
We tried to review and update clinical and preclinical studies evaluating vilazodone's role as an antidepressant for patients with major depressive disorder (MDD). In terms of its mechanism of actions, we sought to elaborate them mainly through preclinical animal studies. A data search was conducted in November 1, 2013, using the key terms "vilazodone" or "Viibryd," in PubMed and Medline databases. All published and unpublished studies are included and citations from publications were also reviewed for additional references. Five unpublished, phase-II and two pivotal published phase-III clinical trials with nearly identical design (8-week, double-blind, randomized, and placebo-controlled) investigated efficacy of vilazodone, were found for the treatment of patients with MDD. Two post-hoc studies and one long-term open study were also included. Data were thoroughly reviewed to incorporate the pharmacology, action mechanism, efficacy and safety for the vilazodone in the treatment of major depressive disorder. Vilazodone is an antidepressant with novel mechanism of action because its chemical structure is unrelated to conventional antidepressant, and it has a selective serotonin (5-HT) reuptake inhibitor and 5-HT1A receptor partial agonist profile. Vilazodone is an effective and safe treatment option with its novel action mechanisms for patients with depression. Its putative benefits compared with other antidepressants must be thoroughly studied in adequately-powered and well-designed future clinical trials.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Vilazodone is a partial agonist at the serotonergic 5-HT1A receptor in addition to its SSRI activity.
“For example, in addition to the SSRI activity, vilazodone is a partial agonist at the serotonergic 5-HT1A receptor94”
From Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review (2018) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988 · see citing works
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · see citing works
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002 · see citing works
Electrophysiological responses of serotoninergic dorsal raphe neurons to 5‐HT1A and 5‐HT1B agonists
Sprouse, J. S., & Aghajanian, G. K. (1987) · Synapse · doi:10.1002/syn.890010103 · Cited by 848 · see citing works
Egede, L. E. (2007) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2007.06.002 · Cited by 638 · see citing works
Treatment-Emergent Sexual Dysfunction Related to Antidepressants: A Meta-Analysis
Serretti, A., & Chiesa, A. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181a5233f · Cited by 583 · see citing works
Is there a role for 5-HT1A agonists in the treatment of depression?
Blier, P., & Ward, N. M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01643-8 · Cited by 529 · see citing works
The therapeutic role of 5-HT1A and 5-HT2A receptors in depression
Celada, P., Puig, M. V., Amargós‐Bosch, M., Adell, A., & Artigas, F. (2004) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0427 · Cited by 523 · see citing works
Celada, P., Bortolozzi, A., & Artigas, F. (2013) · CNS Drugs · doi:10.1007/s40263-013-0071-0 · Cited by 323 · see citing works
Blier, P., Ward, H. E., Tremblay, P., Laberge, L., Hébert, C., & Bergeron, R. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09020186 · Cited by 316 · see citing works
Dawson, L. A., & Watson, J. M. (2009) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00067.x · Cited by 263 · see citing works
GABAB Receptors, Schizophrenia and Sleep Dysfunction
Kantrowitz, J., Citrome, L., & Javitt, D. (2009) · CNS Drugs · doi:10.2165/00023210-200923080-00001 · Cited by 260 · see citing works
Poul, E. L., Laaris, N., Doucet, E., Laporte, A., Hamon, M., & Lanfumey, L. (1995) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00176767 · Cited by 257 · see citing works
Bel, N., & Artigas, F. (1993) · Synapse · doi:10.1002/syn.890150310 · Cited by 237 · see citing works
Citrome, L. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02885.x · Cited by 228 · see citing works
LAUGHREN, T. P., Gobburu, J. V. S., Temple, R. J., Unger, E. F., Bhattaram, A., Dinh, P. V., Fossom, L. H., Hung, H., Klimek, V., Lee, J. E., et al. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11r06984 · Cited by 226 · see citing works
Self-citationBuspirone: What is it all about?
Loane, C., & Politis, M. (2012) · Brain Research · doi:10.1016/j.brainres.2012.04.032 · Cited by 223 · see citing works
Neurobiological Mechanisms Involved in Antidepressant Therapies
Briley, M., & Moret, C. (1993) · Clinical Neuropharmacology · doi:10.1097/00002826-199310000-00002 · Cited by 212 · see citing works
Serotonin autoreceptor function and antidepressant drug action
Hjorth, S., Bengtsson, H. J., Kullberg, A., Carlzon, D., Peilot, H., & Auerbach, S. B. (2000) · Journal of Psychopharmacology · doi:10.1177/026988110001400208 · Cited by 191 · see citing works
Kocsis, J. H., Leon, A. C., Markowitz, J. C., Manber, R., Arnow, B. A., Klein, D. N., & Thase, M. E. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04371 · Cited by 172 · see citing works
Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain.
Blier, P., & Abbott, F. V. (2001) · PubMed Central · Cited by 168 · see citing works
Massart, R., Mongeau, R., & Lanfumey, L. (2012) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2012.0212 · Cited by 167 · see citing works
Li, Q., Muma, N. A., Battaglia, G., & de Kar, L. D. V. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36965-4 · Cited by 149 · see citing works
Evidence for Efficacy and Tolerability of Vilazodone in the Treatment of Major Depressive Disorder
Rickels, K., Athanasiou, M., Robinson, D. S., Gibertini, M., Whalen, H., & Reed, C. R. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04637 · Cited by 145 · see citing works
Citrome, L. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12350 · Cited by 140 · see citing works
Generalized anxiety disorder: diagnosis and treatment
Hoge, E. A., Ivkovic, A., & Fricchione, G. L. (2012) · BMJ · doi:10.1136/bmj.e7500 · Cited by 137 · see citing works
Khan, A., Cutler, A. J., Kajdasz, D. K., Gallipoli, S., Athanasiou, M., Robinson, D. S., Whalen, H., & Reed, C. R. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06596 · Cited by 130 · see citing works
Hughes, Z. A., Starr, K. R., Langmead, C. J., Hill, M., Bartoszyk, G. D., Hagan, J. J., Middlemiss, D. N., & Dawson, L. A. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.01.018 · Cited by 125 · see citing works
The effects of paroxetine and nefazodone on sleep: a placebo controlled trial
Sharpley, A. L., Williamson, D. J., Attenburrow, M. E. J., Pearson, G., Sargent, P. A., & Cowen, P. J. (1996) · Psychopharmacology · doi:10.1007/bf02246410 · Cited by 120 · see citing works
Central 5-HT1A receptors: regional distribution and functional characteristics
Lanfumey, L., & Hamon, M. (2000) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(00)00107-4 · Cited by 119 · see citing works
Casanovas, J. M., Lesourd, M., & Artigas, F. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701420 · Cited by 104 · see citing works
Page, M. E., Cryan, J. F., Sullivan, A., Dalvi, A., Saucy, B., Manning, D. R., & Lucki, I. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.034280 · Cited by 92 · see citing works
Robinson, D. S., Kajdasz, D. K., Gallipoli, S., Whalen, H., Wamil, A., & Reed, C. R. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31822c6741 · Cited by 81 · see citing works
Bartoszyk, G. D., Hegenbart, R., & Ziegler, H. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00999-5 · Cited by 73 · see citing works
Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression
Khan, A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903286396 · Cited by 64 · see citing works
The Effect of Vilazodone on Sexual Function During the Treatment of Major Depressive Disorder
Clayton, A. H., Kennedy, S. H., Edwards, J. B., Gallipoli, S., & Reed, C. R. (2012) · The Journal of Sexual Medicine · doi:10.1111/jsm.12004 · Cited by 60 · see citing works
Hogg, S., & Dalvi, A. (2003) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2003.09.020 · Cited by 56 · see citing works
Starr, K. R., Price, G. W., Watson, J. M., Atkinson, P. J., Arban, R., Melotto, S., Dawson, L. A., Hagan, J. J., Upton, N., & Duxon, M. S. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301341 · Cited by 53 · see citing works
Murck, H., Frieboes, R.-M., Antonijevic, I. A., & Steiger, A. (2001) · Psychopharmacology · doi:10.1007/s002130100703 · Cited by 48 · see citing works
Duxon, M. S., Starr, K. R., & Upton, N. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703496 · Cited by 43 · see citing works
Pharmacological management of unipolar depression
Malhi, G. S., Hitching, R., Berk, M., Boyce, P. M., Porter, R., & Fritz, K. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12122 · Cited by 41 · see citing works
Barowsky, J., & Schwartz, T. L. (2006) · PubMed Central · Cited by 40 · see citing works
A review of current evidence for vilazodone in major depressive disorder
Wang, S., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C. (2013) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2013.794245 · Cited by 40 · see citing works
Self-citationThe influence of ipsapirone, a 5-HT1A agonist, on sleep patterns of healthy subjects
Driver, H. S., Flanigan, M. J., Bentley, A., Mitchell, D., Luus, H. G., & Shapiro, C. M. (1995) · Psychopharmacology · doi:10.1007/bf02245186 · Cited by 39 · see citing works
Clayton, A. H., Reddy, S., Focht, K., Musgnung, J. J., & Fayyad, R. S. (2012) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2012.02899.x · Cited by 30 · see citing works
Hughes, Z. A., Starr, K. R., Scott, C. M., Newson, M. J. F., Sharp, T., Watson, J. M., Hagan, J. J., & Dawson, L. A. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0691-x · Cited by 29 · see citing works
Pharmacokinetics of Vilazodone in Patients with Mild or Moderate Renal Impairment
Boinpally, R., Alcorn, H. W., Adams, M. H., Longstreth, J. A., & Edwards, J. G. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0061-5 · Cited by 28 · see citing works
Vilazodone in the treatment of major depressive disorder
Khan, A., Sambunaris, A., Edwards, J. G., Ruth, A., & Robinson, D. S. (2013) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000016 · Cited by 28 · see citing works
Ashby, C. R., Kehne, J. H., Bartoszyk, G. D., Renda, M. J., Athanasiou, M., Pierz, K. A., & Seyfried, C. A. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.07.014 · Cited by 26 · see citing works
Dose-Related Suppression of REM Sleep and PGO Waves by the Serotonin-1 Agonist Eltoprazine
Quattrochi, J. J., Mamelak, A. N., Binder, D. K., Williams, J. M., & Hobson, J. A. (1993) · Neuropsychopharmacology · doi:10.1038/npp.1993.2 · Cited by 24 · see citing works
Jain, R., Chen, D., Edwards, J., & Mathews, M. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.855188 · Cited by 19 · see citing works
Sorbera, L. A., Rabasseda, X., Silvestre, J. S., & Castañer, J. (2001) · Drugs of the Future · doi:10.1358/dof.2001.026.03.611242 · Cited by 19 · see citing works
Recurrent Seizure Activity in a Child After Acute Vilazodone Ingestion
Carstairs, S. D., Griffith, E. A., Alayin, T., Ejike, J. C., & Cantrell, F. L. (2012) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2012.06.020 · Cited by 16 · see citing works
Vilazodone lacks proarrhythmogenic potential in healthy participants: a thorough ECG study
Edwards, J. G., Sperry, V., Adams, M. H., Gallipoli, S., Thorn, M. D., Longstreth, J. A., & Boinpally, R. (2013) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp201826 · Cited by 13 · see citing works
Vilazodone for the Treatment of Depression
Lindsey, W. T. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1p772 · Cited by 13 · see citing works
Taneja, C., Papakostas, G. I., Jing, Y., Baker, R. A., Forbes, R. A., & Oster, G. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q326 · Cited by 12 · see citing works
Novel Therapeutic Strategies in Major Depression: Focus on RNAi and Ketamine
Bortolozzi, A. A., Celada, P., & Artigas, F. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113196660137 · Cited by 8 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [57]Rush AJ Warden D Wisniewski SR Fava M Trivedi MH Gaynes BN STAR*D: revising conventional wisdom CNS Drugs 2009 23 627 647 19594193
Cited by
Sorted by citations
Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review
Wang, S.-M., Han, C., Bahk, W.-M., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2018) · Chonnam Medical Journal · doi:10.4068/cmj.2018.54.2.101 · Cited by 299 · see citing works
Self-citationNitrile-containing pharmaceuticals: target, mechanism of action, and their SAR studies
Wang, X., Wang, Y. E., Li, X., Yu, Z., Song, C. F., & Du, Y. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00131k · Cited by 211 · see citing works
Vilazodone for the Treatment of Depression: An Update
Wang, S., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C. (2016) · Chonnam Medical Journal · doi:10.4068/cmj.2016.52.2.91 · Cited by 46 · see citing works
Self-citationBundgaard, C., Eneberg, E., & Sánchez, C. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.12.009 · Cited by 40 · see citing works
Vilazodone: A Review in Major Depressive Disorder in Adults
McCormack, P. L. (2015) · Drugs · doi:10.1007/s40265-015-0490-y · Cited by 36 · see citing works
Han, C., Wang, S., Kwak, K., Won, W.-Y., Lee, H.-Y., Chang, C., Tang, T. C., & Pae, C. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.04.020 · Cited by 37 · see citing works
Self-citationDjillani, A., Piétri, M., Moréno, S., Heurteaux, C., Mazella, J., & Borsotto, M. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00643 · Cited by 37 · see citing works
New drugs in psychiatry: focus on new pharmacological targets
Caraci, F., Leggio, G. M., Salomone, S., & Drago, F. (2017) · F1000Research · doi:10.12688/f1000research.10233.1 · Cited by 34 · see citing works
5-HT1A receptor ligands and their therapeutic applications: review of new patents
Staroń, J., Bugno, R., Hogendorf, A. S., & Bojarski, A. J. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1514011 · Cited by 33 · see citing works
Zareifopoulos, N., & Dylja, I. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.01.016 · Cited by 26 · see citing works
Han, C., Wang, S., Lee, S.-J., Jun, T., & Pae, C. (2015) · Chonnam Medical Journal · doi:10.4068/cmj.2015.51.2.66 · Cited by 20 · see citing works
Self-citationБуткевич, И. П., Михайленко, В. А., Vershinina, E. A., & Barr, G. A. (2019) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2019.00125 · Cited by 20 · see citing works
Chavan, B. B., Kalariya, P. D., Tiwari, S. S., Nimbalkar, R. D., Garg, P., Srinivas, R., & Talluri, M. V. N. K. (2017) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.7982 · Cited by 16 · see citing works
Said, H. S. E., Lalatsa, A., Al-mahallawi, A. M., El-Leithy, E. S., & Ghorab, D. M. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122080 · Cited by 14 · see citing works
El‐Kadi, R. A., Abdelkader, N. F., Zaki, H. F., & Kamel, A. S. E. D. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04142-3 · Cited by 14 · see citing works
Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder
Yu, S., Zhang, X., Wu, L., Wan, D., Liu, R., Dong, Z., & Chen, M. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s87968 · Cited by 13 · see citing works
Consistency Is Critical for the Effective Use of Baited Remote Video
Jones, R. E., Griffin, R. A., Herbert, R. J. H., & Unsworth, R. K. F. (2021) · Oceans · doi:10.3390/oceans2010013 · Cited by 13 · see citing works
Five potential therapeutic agents as antidepressants: a brief review and future directions
Wang, S., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1071192 · Cited by 9 · see citing works
Self-citationde Arruda, C. M., Doneda, D. L., de Oliveira, V. V., da Silva, R. A. L., de Matos, Y. A. V., Fernandes, I. L., Rohden, C. A. H., Viola, G. G., Rios-Santos, F., de Lima, E., et al. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2022.173433 · Cited by 8 · see citing works
Zhou, L., Ni, C., Liao, R., Tang, X., Yi, T., Ran, M., Huang, M., Liao, R., Zhou, X., Qin, D., et al. (2024) · eLife · doi:10.7554/elife.94765.3 · Cited by 7 · see citing works
He, H., He, T., & Peng, G. (2018) · Wireless Personal Communications · doi:10.1007/s11277-017-5146-7 · Cited by 7 · see citing works
RetractedSontakke, S., Kadam, R., Tiple, P., Motghare, V. M., Bajait, C., & Kalikar, M. (2020) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_441_18 · Cited by 7 · see citing works
Mondal, P. (2020) · RSC Advances · doi:10.1039/d0ra05559j · Cited by 6 · see citing works
Wu, J., Zhang, Z., Zhang, Q., & Li, J. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117698 · Cited by 5 · see citing works
Ankushe, R. D., Deshmukh, V. S., Chepure, A. H., & Jaju, J. (2022) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2022.v15i9.44812 · Cited by 3 · see citing works
Zhou, L., Ni, C., Liao, R., Tang, X., Yi, T., Ran, M., Huang, M., Liao, R., Zhou, X., Qin, D., et al. (2024) · eLife · doi:10.7554/elife.94765 · Cited by 2 · see citing works
New Treatment Options for Depression: A Primer for Internists
Byun, T. H., Chaliki, S. S., & Poole, K. G. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.01.012 · Cited by 2 · see citing works
Gastó, C., Guarch, J., & Navarro, V. (2015) · Psiquiatría Biológica · doi:10.1016/j.psiq.2015.05.001 · Cited by 2 · see citing works
Vilazodone for major depressive disorder in adults
Song, L., Liu, Y., Liu, F., Zhang, R., Ji, H., & Jia, Y. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012350 · Cited by 1 · see citing works
Aleid, A. M., Alhiqwi, I. J., Alessa, A., Alzahuf, S. M. H., Alzahrani, H., Al-Ramadhan, A. M., Alharthi, A. M., Kariri, A., Alzubaidi, A. S. A., Alharbi, G. J., et al. (2024) · Journal of Advanced Trends in Medical Research · doi:10.4103/atmr.atmr_186_24 · Cited by 1 · see citing works
Arya, N., Nischal, A., Nischal, A., & Agarwal, M. (2020) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20201116
Zhou, L., Ni, C., Liao, R., Tang, X., Yi, T., Ran, M., Huang, M., Liao, R., Zhou, X., Qin, D., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.16.571981
Zhou, L., Ni, C., Liao, R., Tang, X., Yi, T., Ran, M., Huang, M., Liao, R., Zhou, X., Qin, D., et al. (2024) · eLife · doi:10.7554/elife.94765.1
Zhou, L., Ni, C., Liao, R., Tang, X., Yi, T., Ran, M., Huang, M., Liao, R., Zhou, X., Qin, D., et al. (2024) · eLife · doi:10.7554/elife.94765.2
Le récepteur 3 de la neurotensine/Sortiline dans la régulation de l’état dépressif
Moréno, S. (2017) · theses.fr (ABES) · doi:10.70675/bd5432bcz3426z4e54z9081zd99b2eb3f712 · Cited by 1 · see citing works
BindingDB (2024) · UC San Diego · doi:10.7270/q29z993j
- Authors
- Wang, S.-M., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U.
- Affiliations
- Catholic University of Korea (KR)
- Korea University (KR)
- Duke Medical Center (US)
- Global Medical Education, New York, NY, USA.
- Corresponding author
- Pae, Chi-Un
- Venue
- Psychiatry Investigation
- Publisher
- Korean Neuropsychiatric Association
- Published
- 2015
- Volume
- 12
- Issue
- 2
- Pages
- 155
- ISSN
- 1738-3684 (ISSN-L)
- 1976-3026
- PMC
- PMC4390584
- OpenAlex
- W1990376788
- Cited by
- 36
- References
- 57
- Citations by year
- 2025: 1 · 2024: 7 · 2023: 1 · 2022: 3 · 2021: 2 · 2020: 3 · 2019: 2 · 2018: 3 · 2017: 5 · 2016: 2 · 2015: 7
- FWCI
- 0.71
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Psychiatry Investigation (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- vilazodone, major depressive disorder, antidepressants, 5-HT1A receptor partial agonist, selective serotonin reuptake inhibitors, mechanism of action, antidepressant efficacy, drug safety, clinical trials
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
